Daiichi Sankyo Co Ltd 4568
News
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
Merck, Daiichi Sankyo Add Merck's MK-6070 to Collaboration
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
England's NHS Watchdog Denies Access to AstraZeneca's Breast Cancer Drug
FDA Turns Away Daiichi Sankyo, Merck Lung-Cancer ADC
Fusion Pharma climbs as analysts flag radiopharmaceutical company as potential merger target
AstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer Treatment
Trending: Merck, Daiichi Sankyo Sign Development, Commercialization Deal
Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck
Daiichi Sankyo Shares Jump on Multibillion-Dollar Drug Development Deal With Merck